Sglt2 Inhibitor

Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users, according to data from researchers in Taiwan.

AUSTIN, Texas — Results presented here showed that combining SGLT2 inhibitors and mineralocorticoid receptor antagonists was effective in reducing the urinary albumin creatinine ratio in patients with type 2 diabetes.

Patients with heart failure who received an SGLT2 inhibitor were less likely to experience sudden cardiac death compared with those who received placebo, according to a study in Clinical Cardiology.

SGLT2 inhibitor therapy in patients with heart failure is associated with a significantly lower incidence of sudden cardiac death vs. placebo, with the benefit persisting independent of other guideline-directed medical therapies.

Compared with glucagon-like peptide-1 receptor agonists, patients with chronic kidney disease and type 2 diabetes experienced increased risks when taking SGLT2 inhibitors, according to published data.

Researchers estimated that more than 80% of adults in the United States meet the criteria for GLP-1 receptor agonists or SGLT2 inhibitors, but only about one in 10 used either medication from 2017 to 2020.

SGLT2 inhibitors were associated with a lower risk for major adverse cardiovascular events and heart failure hospitalization compared with DPP-4 inhibitors among patients with type 2 diabetes, regardless of baseline HbA1c levels, data show

Disparities by sex, race and between individual U.S. Veterans Affairs facilities exist in SGLT2i prescriptions for veterans with chronic kidney disease, type 2 diabetes mellitus and atherosclerotic cardiovascular disease, researchers found.

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.

Black and older patients with chronic kidney disease and insured by Medicare are less likely to start SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists than second-generation sulfonylureas, according to data in Kidney Medicine.